Applications of Methodology. To demonstrate the utility of this method, we prepared chiral sulfonimidamide analogs of the antitumor agent tasisulam and the antiplatelet drug elinogrel (Figure ). Coupling 4pa with 2,4-dichlorobenzoic acid 6 using a standard 1-[bis(dimethylamino)methylene]-1H-1,2,3triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU)/N,N-diisopropylethylamine (DIPEA) protocol followed by TFA deprotection using ammonia produced the tasisulam-sulfonimidamide analog 7 in 74% yield with no erosion in enantioselectivity, demonstrating the stability of these sulfonimidamide products to a highly enabling reaction. The elinogrel-sulfonimidamide analog 9 was synthesized in a threestep, one-pot procedure. Substrate 4pa was reacted with p-nitrophenyl chloroformate to produce the corresponding carbamate, which reacted with 8 to form the unsymmetrical urea. Lastly, TFA deprotection gave the product in 42% yield and retained stereochemical integrity at 98:2 er.